First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

Díaz‐Rubio, Eduardo; Gómez‐España, Auxiliadora; Massutí, Bartomeu; Sastre, Javier; Abad, Albert; Valladares, Manuel; Rivera, Fernando; José Safont, María; Martínez de Prado, Purificación; Gallén, Manuel; González‐Flores, Encarnación; Marcuello, Eugenio; Benavides, Manuel; Fernández-Martos, Carlos; Losa, Ferrán; Escudero, P.; Arriví, A.; Cervantes, Andrés; Dueñas, Rosario; López-Ladrón, Amelia; Lacasta, Adelaida; Llanos, Marta; Tabernero, Josep; Antón, Antonio; Aranda, Enrique; Cooperative Group for the Treatment of Digestive Tumors (TTD), Spanish

doi:10.1634/theoncologist.2011-0249

Public

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

Published in The Oncologist • Jan 1, 2012

Authors:

Eduardo Díaz‐Rubio

Auxiliadora Gómez‐España

Bartomeu Massutí

Abstract

PURPOSE: The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with ...

Subject

Bevacizumab

Medicine

Capecitabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!